Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Lindenmann, J; Fink-Neuboeck, N; Pichler, M; Anegg, U; Maier, A; Smolle, J; Smolle-Juettner, FM.
Stage-based treatment for thymoma in due consideration of thymectomy: a single-center experience and comparison with the literature.
World J Surg Oncol. 2015; 13(2):303-303
Doi: 10.1186/s12957-015-0718-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Lindenmann Jörg
- Co-Autor*innen der Med Uni Graz
- Anegg Udo
- Fink-Neuböck Nicole
- Maier Alfred
- Pichler Martin
- Smolle Josef
- Smolle-Juettner Freyja-Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Thymomas represent an uncommon and heterogeneous group of intrathoracic malignancies which require different treatments corresponding to their individual tumor stage. The objective of this study was to review the efficacy of our applied stage-based treatment for thymoma in due consideration of thymectomy. This is a single-center, institutional review board-approved retrospective study of 50 consecutive patients with thymoma treated at our division within 10 years. There were 29 women (58 %) and 21 men (42 %), mean age 58.3 years. Twenty nine (58 %) had clinical symptoms and 14 (28 %) had myasthenia gravis. Forty-five patients (90 %) underwent thymectomy and complete resection was done in 42 cases (93.3 %). Histologic results were 6 subtype A, 5 AB, 8 B1, 12 B2, 12 B3, and 7 C. The Masaoka staging system revealed 20 stage I, 18 stage II, 6 stage III, and 6 stage IV. Two patients had neoadjuvant therapy and 25 received postoperative treatment. Five (11.1 %) had tumor recurrence, treated with re-resection. The 5-year disease-free survival was 91.5 %. Two patients died of tumor progression and three died of other causes (10 %). The 5-year overall survival was 82.3 % and the median survival time was 92.1 months. The 5-year survival rate after thymectomy was 87.2 % and the median survival was 92.1 months. Complete resection still remains the mainstay in the treatment of non-metastatic thymoma and should be performed whenever feasible. Close multidisciplinary teamwork is mandatory to optimize the neurologic outcome and to prolong postoperative survival.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Disease-Free Survival -
- Female -
- Humans -
- Male -
- Middle Aged -
- Neoplasm Staging -
- Retrospective Studies -
- Survival Rate -
- Thymectomy -
- Thymoma - mortality
- Thymus Neoplasms - mortality
- Treatment Outcome -
- Young Adult -
- Find related publications in this database (Keywords)
- Thymoma
- Surgery
- Thymectomy
- Myasthenia gravis
- Survival